PT1889848E - Derivado de 7-carbamoíl-morfinano insaturado em 6,7 - Google Patents

Derivado de 7-carbamoíl-morfinano insaturado em 6,7 Download PDF

Info

Publication number
PT1889848E
PT1889848E PT67468330T PT06746833T PT1889848E PT 1889848 E PT1889848 E PT 1889848E PT 67468330 T PT67468330 T PT 67468330T PT 06746833 T PT06746833 T PT 06746833T PT 1889848 E PT1889848 E PT 1889848E
Authority
PT
Portugal
Prior art keywords
optionally substituted
group
compound
substituents
quot
Prior art date
Application number
PT67468330T
Other languages
English (en)
Portuguese (pt)
Inventor
Masanao Inagaki
Shin-Ichiro Hara
Nobuhiro Haga
Yoshinori Tamura
Tsuyoshi Hasegawa
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PT1889848E publication Critical patent/PT1889848E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT67468330T 2005-05-25 2006-05-25 Derivado de 7-carbamoíl-morfinano insaturado em 6,7 PT1889848E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2006065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (ja) 2005-05-25 2006-05-23 ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体

Publications (1)

Publication Number Publication Date
PT1889848E true PT1889848E (pt) 2014-12-09

Family

ID=37451954

Family Applications (1)

Application Number Title Priority Date Filing Date
PT67468330T PT1889848E (pt) 2005-05-25 2006-05-25 Derivado de 7-carbamoíl-morfinano insaturado em 6,7

Country Status (20)

Country Link
US (4) USRE46365E1 (OSRAM)
EP (1) EP1889848B8 (OSRAM)
JP (1) JP4323547B2 (OSRAM)
KR (1) KR100912782B1 (OSRAM)
CN (1) CN101228172B (OSRAM)
AU (1) AU2006250390B2 (OSRAM)
BE (1) BE2019C533I2 (OSRAM)
BR (1) BRPI0610343B8 (OSRAM)
CA (1) CA2609733C (OSRAM)
DK (1) DK1889848T3 (OSRAM)
ES (1) ES2525215T3 (OSRAM)
FR (1) FR19C1042I2 (OSRAM)
HU (1) HUS1900034I1 (OSRAM)
MX (1) MX2007014588A (OSRAM)
NL (1) NL300996I2 (OSRAM)
PL (1) PL1889848T3 (OSRAM)
PT (1) PT1889848E (OSRAM)
RU (1) RU2403255C2 (OSRAM)
TW (1) TWI311056B (OSRAM)
WO (2) WO2006126529A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
CA3066426A1 (en) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
JP5252391B2 (ja) * 2008-02-21 2013-07-31 学校法人北里研究所 オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途
US20110237614A1 (en) * 2008-09-16 2011-09-29 Nektar Therapeutics Pegylated Opioids with Low Potential for Abuse
JP5797655B2 (ja) * 2009-09-18 2015-10-21 アドラー・コーポレーション 消化管障害のためのオピオイド受容体アンタゴニストの使用
US20130217672A1 (en) * 2010-05-13 2013-08-22 Green Cross Corporation (+)-3-hydroxymorphinan-based polycycle derivatives
CA2814195C (en) * 2010-11-12 2020-03-10 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same
EP2851075B1 (en) 2012-05-14 2021-12-01 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoylmorphinan derivative
CA3048360C (en) 2016-12-26 2021-06-29 Shionogi & Co., Ltd. Production method for formulation having improved content uniformity
WO2019200202A1 (en) 2018-04-12 2019-10-17 Morphic Therapeutic, Inc. Antagonists of human integrin (alpha4)(beta7)
KR102201609B1 (ko) 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
TWI775182B (zh) 2019-10-16 2022-08-21 美商莫菲克醫療股份有限公司 抑制人類整合素αβ
WO2021100728A1 (ja) 2019-11-20 2021-05-27 塩野義製薬株式会社 ６，７－不飽和－７－カルバモイルモルヒナン誘導体含有固形製剤
CN111905111B (zh) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法
IT202300009864A1 (it) * 2023-05-16 2024-11-16 Procos Spa Processo per la preparazione di naldemedina

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
ES2146654T3 (es) 1993-07-23 2000-08-16 Toray Industries Derivado de morfinano y uso medico.
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
CA2242609A1 (en) 1996-01-10 1997-07-17 Smithkline Beecham S.P.A. Heterocycle-condensed morphinoid derivatives (ii)
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
DE60032940T2 (de) * 1999-11-29 2007-11-08 Adolor Corp. Neue verfahren und zubereitungen die opioiden und deren antagonisten enthalten
AU2001259560B2 (en) 2000-05-05 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
AU5945801A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Opoid antagonist compositions and dosage forms
CA2426942C (en) 2000-10-31 2014-06-03 Mark P. Wentland 8-carboxamido-2,6-methano-3-benzazocines
ATE402179T1 (de) 2000-11-22 2008-08-15 Toray Industries Indolderivate und deren verwendung in medikamenten
BRPI0211899B8 (pt) * 2001-08-23 2021-05-25 Akzo Nobel Nv processos para a preparação de um derivado de 14- hidroxinormorfinona e para a produção de noroximorfona
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
DE10229842A1 (de) * 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
EP1522542A1 (en) * 2002-07-11 2005-04-13 Toray Industries, Inc. Therapeutic or preventive agent for nausea/vomiting
CA2498046A1 (en) 2002-09-18 2004-04-01 The Curators Of The University Of Missouri Opiate analogs selective for the delta-opioid receptor
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
DK1758452T3 (en) 2004-05-28 2017-05-01 Human Biomolecular Res Inst METABOLIC STABLE ANALGETICS AND Painkillers
US20060063792A1 (en) 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device
WO2006126529A1 (ja) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
CA2814195C (en) 2010-11-12 2020-03-10 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same

Also Published As

Publication number Publication date
BRPI0610343B8 (pt) 2021-05-25
TWI311056B (en) 2009-06-21
PL1889848T3 (pl) 2015-04-30
ES2525215T3 (es) 2014-12-19
US8084460B2 (en) 2011-12-27
RU2403255C2 (ru) 2010-11-10
US20120135978A1 (en) 2012-05-31
HUS1900034I1 (hu) 2019-07-29
EP1889848B1 (en) 2014-10-15
NL300996I2 (nl) 2019-07-30
CA2609733A1 (en) 2006-11-30
EP1889848A4 (en) 2011-08-10
USRE46365E1 (en) 2017-04-11
USRE46375E1 (en) 2017-04-25
MX2007014588A (es) 2008-01-24
KR20080014791A (ko) 2008-02-14
JP4323547B2 (ja) 2009-09-02
US8536192B2 (en) 2013-09-17
JPWO2006126637A1 (ja) 2008-12-25
BE2019C533I2 (OSRAM) 2025-12-10
NL300996I1 (nl) 2019-07-03
KR100912782B1 (ko) 2009-08-18
WO2006126529A1 (ja) 2006-11-30
FR19C1042I1 (OSRAM) 2019-08-09
WO2006126637A1 (ja) 2006-11-30
RU2007148412A (ru) 2009-06-27
AU2006250390A1 (en) 2006-11-30
EP1889848A1 (en) 2008-02-20
EP1889848B8 (en) 2014-12-17
BRPI0610343A2 (pt) 2010-06-15
CN101228172A (zh) 2008-07-23
DK1889848T3 (en) 2014-12-01
AU2006250390B2 (en) 2010-07-08
US20090203723A1 (en) 2009-08-13
FR19C1042I2 (fr) 2020-06-19
TW200726470A (en) 2007-07-16
BRPI0610343B1 (pt) 2020-03-10
CN101228172B (zh) 2013-04-03
CA2609733C (en) 2011-07-19

Similar Documents

Publication Publication Date Title
PT1889848E (pt) Derivado de 7-carbamoíl-morfinano insaturado em 6,7
ES2772498T3 (es) Preparación de un inhibidor mek y formulación que comprende el mismo
ES2746207T3 (es) Derivado cristalino de 6,7-insaturado-7-carbamoilmorfinano y método de producción del mismo
TWI723511B (zh) 一種高活性sting蛋白激動劑化合物
JP2013523599A (ja) 新規なオピオイドのジカルボン酸結合アミノ酸及びペプチドプロドラッグ並びにその用途
KR20160127761A (ko) C형 간염 바이러스 억제제 및 약품 제조에서의 이의 용도
CN107922340B (zh) 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用
JP6215399B2 (ja) ナルトレキソンの製造方法
PT723544E (pt) Carbamatos de alcoxialquilo de imidazo¬1,2-a|piridinas
JP7667742B2 (ja) Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法
EP1342723B1 (en) Indole derivatives and use thereof in medicines
CN115066423B (zh) Pd-l1拮抗剂化合物
AU2022347450A1 (en) Erk5 degraders and uses thereof
HK40121692A (zh) 一种tdg抑制剂化合物及其用途
CN101070291A (zh) N－or酰胺类化合物,其制备方法和其应用
CN103237804A (zh) 制备纳曲酮的方法
WO2006064779A1 (ja) ６’位にカルボキシを有するインドロモルヒナン誘導体
CN101119728A (zh) 6’位上具有羧基的吲哚并吗啡喃衍生物